PBYI
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Financial indicators Supports a bullish reading. Current ratio 2.00 · operating margin 16%
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 67 150 titres (~612 494,45 $ US)
- Insiders
- WILSON TROY EDWARDCesano Alessandra
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$612,494
Avg sell (VWAP, 90d window) $8.71 vs last close —
- Last activity
- 2026-09-14
- Last synced
-
2026-09-20 09:54:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Cesano Alessandra | Sell | 62,150 | $9.12 | $566,994 | Form 4 |
| 2026-09-14 | WILSON TROY EDWARD | Sell | 5,000 | $9.10 | $45,500 | Form 4 |
| 2026-07-06 | AUERBACH ALAN H | Sell | 44,058 | $8.26 | $364,051 | Form 4 |
| 2026-07-06 | HUNT DOUGLAS M | Sell | 8,460 | $8.26 | $69,905 | Form 4 |
| 2026-07-06 | NOUGUES MAXIMO F | Sell | 9,386 | $8.26 | $77,557 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-18
PBYI presents a compelling combination of strong financial health (liquidity: 80, fundamentals: 85) and a moderate earnings catalyst (65) anchored by a Q2 beat, raised 2026 guidance, and a new Phase II trial for…
The first sentence of the analysis written for PBYI on 2026-09-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | |
| Ebit Margin | 18.6% | 15.9% | 15.3% | 5.3% | -6.3% | |
| Ebitda Margin | 23.4% | 20.9% | 20.2% | 9.6% | -1.9% | |
| Operating Profit Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | |
| Pretax Profit Margin | 15.7% | 10.5% | 9.6% | 0.2% | -11.4% | |
| Continuous Operations Profit Margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | |
| Net Profit Margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | |
| Bottom Line Profit Margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | |
| Current Ratio | 2.002 | 1.536 | 1.572 | 1.733 | 1.278 | |
| Quick Ratio | 1.934 | 1.446 | 1.500 | 1.675 | 1.213 | |
| Solvency Ratio | 0.489 | 0.345 | 0.187 | 0.049 | -0.078 | |
| Cash Ratio | 0.365 | 0.720 | 0.851 | 0.983 | 0.576 | |
| Price To Earnings Ratio | 9.597 | 4.919 | 9.413 | 207.353 | -4.222 | |
| Price To Earnings Growth Ratio | 0.000 | 0.141 | 0.004 | -2.016 | 0.080 | |
| Forward Price To Earnings Growth Ratio | 0.000 | 0.141 | 0.004 | -2.016 | 0.080 | |
| Price To Earnings Diluted Ratio | 9.754 | 4.919 | 9.622 | 208.374 | -4.222 | |
| Price To Earnings Diluted Growth Ratio | -6.048 | 0.130 | 0.005 | -2.027 | 0.080 | |
| Price To Book Ratio | 2.283 | 1.611 | 3.819 | 8.746 | -50.508 | |
| Price To Sales Ratio | 1.303 | 0.644 | 0.866 | 0.829 | 0.488 | |
| Price To Free Cash Flow Ratio | 7.131 | 3.818 | 14.204 | -8.278 | 5.983 | |
| Price To Operating Cash Flow Ratio | 7.119 | 3.813 | 7.556 | -11.940 | 5.983 | |
| Debt To Assets Ratio | 0.132 | 0.347 | 0.484 | 0.515 | 0.515 | |
| Debt To Equity Ratio | 0.219 | 0.804 | 2.086 | 5.289 | -47.686 | |
| Debt To Capital Ratio | 0.180 | 0.446 | 0.676 | 0.841 | 1.021 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.191 | 0.551 | 0.820 | 1.026 | |
| Financial Leverage Ratio | 1.660 | 2.316 | 4.314 | 10.277 | -92.635 | |
| Working Capital Turnover Ratio | 3.435 | 4.254 | 4.149 | 5.228 | 8.124 | |
| Operating Cash Flow Ratio | 0.514 | 0.405 | 0.272 | -0.204 | 0.188 | |
| Operating Cash Flow Sales Ratio | 0.183 | 0.169 | 0.115 | -0.069 | 0.082 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.998 | 0.999 | 0.532 | 1.442 | 1.000 | |
| Debt Service Coverage Ratio | 1.670 | 0.939 | 0.981 | 1.849 | -0.392 | |
| Interest Coverage Ratio | 5.633 | 2.487 | 2.449 | 2.046 | 0.101 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.856 | 0.859 | 0.794 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.464 | 0.525 | 0.242 | -0.138 | 0.177 | |
| Capital Expenditure Coverage Ratio | 588.761 | 694.964 | 2.137 | -2.261 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 588.761 | 694.964 | 2.137 | -2.261 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 5.558 | 3.187 | 4.861 | 10.373 | -37.751 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.5% | ▲2.5% | ▲0.4% |
| Ebit Margin | 18.6% | ▲2.7% | ▲8.8% |
| Ebitda Margin | 23.4% | ▲2.5% | ▲8.9% |
| Operating Profit Margin | 16.3% | ▲2.9% | ▲5.4% |
| Pretax Profit Margin | 15.7% | ▲5.2% | ▲10.8% |
| Continuous Operations Profit Margin | 13.6% | ▲0.5% | ▲8.7% |
| Net Profit Margin | 13.6% | ▲0.5% | ▲8.7% |
| Bottom Line Profit Margin | 13.6% | ▲0.5% | ▲8.7% |
| Current Ratio | 2.002 | ▲0.466 | ▲0.378 |
| Quick Ratio | 1.934 | ▲0.489 | ▲0.381 |
| Solvency Ratio | 0.489 | ▲0.144 | ▲0.291 |
| Cash Ratio | 0.365 | ▼-0.355 | ▼-0.334 |
| Price To Earnings Ratio | 9.597 | ▲4.677 | ▼-35.815 |
| Price To Earnings Growth Ratio | 0.000 | ▼-0.141 | ▲0.358 |
| Forward Price To Earnings Growth Ratio | 0.000 | ▼-0.141 | ▲0.358 |
| Price To Earnings Diluted Ratio | 9.754 | ▲4.835 | ▼-35.935 |
| Price To Earnings Diluted Growth Ratio | -6.048 | ▼-6.178 | ▼-4.476 |
| Price To Book Ratio | 2.283 | ▲0.672 | ▲9.093 |
| Price To Sales Ratio | 1.303 | ▲0.659 | ▲0.477 |
| Price To Free Cash Flow Ratio | 7.131 | ▲3.312 | ▲2.559 |
| Price To Operating Cash Flow Ratio | 7.119 | ▲3.306 | ▲4.612 |
| Debt To Assets Ratio | 0.132 | ▼-0.215 | ▼-0.267 |
| Debt To Equity Ratio | 0.219 | ▼-0.585 | ▲8.077 |
| Debt To Capital Ratio | 0.180 | ▼-0.266 | ▼-0.453 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.191 | ▼-0.517 |
| Financial Leverage Ratio | 1.659 | ▼-0.656 | ▲16.473 |
| Working Capital Turnover Ratio | 3.435 | ▼-0.820 | ▼-1.603 |
| Operating Cash Flow Ratio | 0.514 | ▲0.110 | ▲0.279 |
| Operating Cash Flow Sales Ratio | 0.183 | ▲0.014 | ▲0.087 |
| Free Cash Flow Operating Cash Flow Ratio | 0.998 | ▼-0.000 | ▲0.004 |
| Debt Service Coverage Ratio | 1.670 | ▲0.731 | ▲0.660 |
| Interest Coverage Ratio | 5.633 | ▲3.146 | ▲3.090 |
| Short Term Operating Cash Flow Coverage Ratio | 1.856 | ▲0.997 | ▲1.154 |
| Operating Cash Flow Coverage Ratio | 1.464 | ▲0.939 | ▲1.010 |
| Capital Expenditure Coverage Ratio | 588.761 | ▼-106.204 | ▲332.040 |
| Dividend Paid And Capex Coverage Ratio | 588.761 | ▼-106.204 | ▲332.040 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 5.558 | ▲2.371 | ▲8.312 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $297.6M | $148.4M | $204.1M | $189.0M | $123.5M | |
| Enterprise value | $296.5M | $153.2M | $231.0M | $227.1M | $177.1M | |
| EV / Sales | 1.30x | 0.67x | 0.98x | 1.00x | 0.70x | |
| EV / Op. cash flow | 7.09x | 3.94x | 8.55x | -14.35x | 8.57x | |
| EV / Free cash flow | 7.11x | 3.94x | 16.08x | -9.95x | 8.57x | |
| EV / EBITDA | 5.56x | 3.19x | 4.86x | 10.37x | -37.75x | |
| Net debt / EBITDA | -0.02x | 0.10x | 0.57x | 1.74x | -11.41x | |
| Current ratio | 2.00x | 1.54x | 1.57x | 1.73x | 1.28x | |
| Income quality | 1.34x | 1.28x | 1.25x | -7913.50x | -0.71x | |
| Graham number | $6 | $5 | $3 | $0 | — | |
| Graham net-net | $1 | $0 | -$1 | -$2 | -$3 | |
| Tax burden | 86.9% | 125.6% | 95.2% | 0.4% | 101.1% | |
| Interest burden | 84.4% | 65.9% | 63.0% | 3.8% | 180.1% | |
| Working capital | $81.4M | $51.5M | $56.8M | $56.8M | $30.4M | |
| Invested capital | $128.4M | $107.8M | $126.3M | $139.9M | $112.3M | |
| Return on assets | 14.4% | 14.2% | 9.4% | 0.0% | -12.9% | |
| Operating ROA | 17.4% | 14.0% | 14.4% | 10.6% | 0.5% | |
| Return on tangible assets | 17.8% | 18.7% | 12.7% | 0.0% | -18.2% | |
| Return on equity | 23.9% | 32.9% | 40.4% | 0.0% | 1190.8% | |
| Return on invested capital | 20.4% | 18.4% | 18.3% | 0.1% | 1.1% | |
| Return on capital employed | 27.6% | 26.4% | 24.9% | 16.4% | 1.1% | |
| Earnings yield | 10.5% | 20.4% | 10.6% | 0.0% | -23.6% | |
| Free cash flow yield | 14.0% | 26.2% | 7.0% | -12.1% | 16.7% | |
| Capex / Op. cash flow | 0.2% | 0.1% | 46.8% | -44.2% | 0.0% | |
| Capex / Depreciation | 0.6% | 0.5% | 109.7% | 71.1% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 5.4% | 3.1% | 0.0% | |
| SG&A / Sales | 31.2% | 34.8% | 37.9% | 39.5% | 45.9% | |
| R&D / Sales | 27.2% | 23.8% | 21.4% | 22.9% | 28.4% | |
| Stock comp / Sales | 3.0% | 3.6% | 4.3% | 5.2% | 12.9% | |
| Intangibles / Total assets | 19.1% | 24.0% | 26.4% | 31.8% | 29.2% | |
| Days sales outstanding | 86d | 51d | 75d | 68d | 47d | |
| Days payables outstanding | 32d | 31d | 40d | 43d | 64d | |
| Operating cycle | 120d | 100d | 116d | 98d | 88d | |
| Cash conversion cycle | 89d | 69d | 76d | 55d | 24d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+100.5%EV / Sales ▲+95.2%EV / EBITDA ▲+74.4%EV / Op. cash flow ▲+3.155Earnings yield ▼-0.100Graham number ▲+0.890
Profitability
Return on equity ▼-0.090Return on assets ▲+0.002Return on invested capital ▲+0.020Return on capital employed ▲+0.012Operating ROA ▲+0.034Income quality ▲+0.058Tax burden ▼-0.387
Efficiency
Days sales outstanding ▲+35.057Days payables outstanding ▲+0.511Operating cycle ▲+20.228Cash conversion cycle ▲+19.717Capex / Sales +0.000R&D / Sales ▲+0.033
Balance-sheet strength
Current ratio ▲+0.466Net debt / EBITDA ▼-0.122Working capital ▲+29886000.000Invested capital ▲+20613000.000Intangibles / Total assets ▼-0.048
Change over 5 years
Valuation
Market cap ▲+140.9%EV / Sales ▲+85.6%EV / EBITDA ▲+114.7%EV / Op. cash flow ▼-1.481Earnings yield ▲+0.340
Profitability
Return on equity ▼-11.669Return on assets ▲+0.272Return on invested capital ▲+0.193Return on capital employed ▲+0.265Operating ROA ▲+0.168Income quality ▲+2.053Tax burden ▼-0.142
Efficiency
Days sales outstanding ▲+38.858Days payables outstanding ▼-32.294Operating cycle ▲+32.737Cash conversion cycle ▲+65.031Capex / Sales n/aR&D / Sales ▼-0.012
Balance-sheet strength
Current ratio ▲+0.724Net debt / EBITDA ▲+11.389Working capital ▲+50997000.000Invested capital ▲+16051000.000Intangibles / Total assets ▼-0.100
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-05-15 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-01-23 | Donna Shalala | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-18 PBYI''s Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
- 2026-09-17 Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
- 2026-09-09 Puma Biotechnology to Present at H.C. Wainwright''s 28th Annual Global Investment Conference LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright''s 28th Annual Global Investment Conf.
- 2026-09-08 Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise NERLYNX gives PBYI an established revenue stream that can support alisertib''s development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib''s biomarker strategy could identify responsive patients, but bear in mind that it''s still a speculative asset in Phase 2 trials.
- 2026-09-03 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
- 2026-09-02 3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc. BlackRock Inc. bought a new stake in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,804,736 shares of the biopharmaceutical company''s stock, valued at approximately $30,856,000. BlackRock Inc. owned 7.47% of
- 2026-08-12 Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 2026-08-07 PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
- 2026-08-07 Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
- 2026-08-07 Puma Biotechnology Q2 Earnings Call Highlights Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.